Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320020 | 0.76 | ERN1 (0.41) | ERN1POLBTDP1NNMTCYP1A2 | |
| SCHEMBL4980644 | 0.76 | ERN1 (0.46) | ERN1POLBTDP1NNMTCYP1A2 | |
| SCHEMBL2261210 | 0.76 | CYP1A2 (0.44) | ERN1POLBTDP1PDE10ANNMT | |
| SCHEMBL23887458 | 0.74 | MAP4K4 (0.36) | POLBTDP1PDE10ANNMTCYP1A2 | |
| SCHEMBL30266908 | 0.74 | MAP4K4 (0.36) | POLBTDP1PDE10ANNMTCYP1A2 | |
| SCHEMBL29950831 | 0.74 | ERN1 (0.44) | ERN1POLBTDP1NNMTCYP1A2 | |
| SCHEMBL29432648 | 0.74 | ERN1 (0.42) | ERN1POLBTDP1PDE10ANNMT | |
| SCHEMBL29957674 | 0.74 | NFE2L2 (0.40) | ERN1POLBTDP1PDE10ANNMT | |
| SCHEMBL20531048 | 0.74 | ERN1 (0.42) | ERN1POLBTDP1PDE10ANNMT | |
| SCHEMBL28997057 | 0.74 | NFE2L2 (0.40) | ERN1POLBTDP1PDE10ANNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050401-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, RET | ERN1 1995/4885POLB 1954/4885TDP1 1496/4885 |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | ERN1 1292/4885POLB 1852/4885TDP1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.